GRAIL Reports $40.8 Million Revenue in Q1 2026, Driven by 37% Increase in Screening Revenue

GRAIL, Inc. reported a total revenue of $40.8 million for the first quarter of 2026, marking a 28% increase from $31.8 million in the same period of 2025. The growth was primarily driven by a 37% rise in screening revenue, which reached $39.8 million, attributed to a 50% increase in sales volume of its Galleri test. However, the average selling price (ASP) for the test decreased by 9%, impacting overall revenue. Development services revenue, on the other hand, fell significantly by 65% to $953,000, largely due to reduced revenue from biopharmaceutical partnerships.

In terms of expenses, GRAIL reported total costs and operating expenses of $176.6 million, a decrease from $185.4 million in the prior year. This reduction was influenced by lower research and development costs, which fell by 10% to $48 million, and a 12% decrease in sales and marketing expenses. The company recorded a net loss of $93.2 million for the quarter, an improvement from the $106.2 million loss reported in the same quarter of 2025. The loss per share also improved to $(2.29) from $(3.10) year-over-year.

Operationally, GRAIL has made significant strides in expanding its customer base, with over 19,000 prescribers now utilizing the Galleri test. The company has processed over 860,000 tests since its inception, with 56,000 tests sold in the first quarter of 2026 alone. GRAIL's cash and cash equivalents stood at $69.3 million, alongside $753.8 million in short-term marketable securities, providing a solid liquidity position to support ongoing operations and investments.

Strategically, GRAIL is focused on enhancing its market presence and product adoption. The company is pursuing FDA approval for Galleri, which it submitted in January 2026, and is actively working to secure broader reimbursement coverage. Additionally, GRAIL is exploring international expansion opportunities, including potential launches in the UK and partnerships in South Korea with Samsung. The company anticipates continued investment in research and development, particularly in clinical studies to support the efficacy of its products.

Looking ahead, GRAIL expects to continue incurring operating losses as it invests in commercialization and research efforts. The company believes its existing cash and marketable securities will be sufficient to meet its operational needs for at least the next 12 months. However, it acknowledges the necessity of raising additional capital in the future to support its growth initiatives and navigate the evolving landscape of multi-cancer early detection testing.